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Summary
We investigated the risk of
thromboembolic disease
(TED) after radiation therapy
(RT) with curative intent for
prostate cancer in a cohort
including 6232 men who
received external beam RT
(EBRT) and 3178 who un-
derwent brachytherapy (BT).
No significant associations
Purpose: To investigate the risk of thromboembolic disease (TED) after radiation ther-
apy (RT) with curative intent for prostate cancer (PCa).
Patients and Methods: We identified all men who received RT as curative treatment
(nZ9410) and grouped according to external beam RT (EBRT) or brachytherapy
(BT). By comparing with an age- and county-matched comparison cohort of PCa-
free men (nZ46,826), we investigated risk of TED after RT using Cox proportional
hazard regression models. The model was adjusted for tumor characteristics, demo-
graphics, comorbidities, PCa treatments, and known risk factors of TED, such as
recent surgery and disease progression.
Results: Between 2006 and 2013, 6232 men with PCa received EBRT, and 3178 un-
derwent BT. A statistically significant association was found between EBRT and BT
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were found between EBRT or
BT and risk of deep venous
thromboembolism or pulmo-
nary embolism. Curative RT
for prostate cancer using
contemporary methodologies
was thus not associated with
an increased risk of TED.
and risk of pulmonary embolism in the crude analysis. However, upon adjusting for
known TED risk factors these associations disappeared. No significant associations
were found between BT or EBRT and deep venous thrombosis.
Conclusion: Curative RT for prostate cancer using contemporary methodologies was
not associated with an increased risk of TED.  2017 The Authors. Published by Else-
vier Inc. This is an open access article under the CC BY-NC-ND license (http://
creativecommons.org/licenses/by-nc-nd/4.0/).
Introduction
Cancer increases the risk of embolic or thromboembolic
diseases (TED) because tumor cells can activate the coag-
ulation system (1). Previously we have shown that men
with prostate cancer (PCa) are at higher risk of TED (2),
and this risk was especially high for those who had un-
dergone PCa-related surgeries while receiving androgen
deprivation therapy (ADT) (3).
No large epidemiologic study has yet investigated the
association between radiation therapy (RT) and risk of
TED. It has been suggested that veins are less susceptible to
radiation effects; however, there are several case reports of
arterial thrombosis for patients who received RT for breast,
lung, or uterine cancer (4-6). There is also a considerable
body of experimental and epidemiologic evidence showing
that RT causes damage to endothelial cells in the arteries
via different mechanisms (7). For instance, the association
between RT for breast cancer and higher risk of myocardial
infarction and coronary heart disease is well established
(8, 9). On the basis of this evidence, endothelial damage to
veins is possible, and therefore quantifying the risk of TED
after RT is of relevance.
In this study we investigated the association between
curative RT given with contemporary standards for prostate




We selected all men with PCa who received curative RT for
prostate cancer between 1996 and 2013, as registered in
Prostate Cancer data Base Sweden (PCBaSe) (nZ9410),
which is described in detail elsewhere (Fig. 1) (10, 11).
Briefly, PCBaSe Sweden was created by linking the
National Prostate Cancer Register (NPCR) of Sweden with
a number of other population-based registers via the use of
the Swedish personal identity number. It also contains a
control series of men free of PCa at the time of sampling.
These men were matched by county of residence and birth
year with an index case. For the present study we selected
46,826 men free of PCa. This comparison with a non-PCa
cohort has been successfully applied previously in Prostate
Cancer data Base Sweden when investigating the risk of
TED, cardiovascular disease, or diabetes after ADT or
surgery (2, 3, 12-14). Radiation therapy data were obtained
from the NPCR, as well as from RetroRadioTherapy, a
separate retrospective data collection at radiation units in
Sweden. For this register data on treatment type, timing,
total dose, and fractionation were retrieved directly from
the verification/oncology information systems and local
databases of the RT departments in Sweden. Men were
followed up starting on the day of RT until the end of the
study, death, immigration, or loss to follow-up. Prostate
cancerefree men inherited an RT date according to their
matched PCa men. The Research Ethics Board at Umea
University approved this study (11).
The main outcomes were deep venous thrombosis
(DVT) (International Classification of Diseases, 10th revi-
sion code: I80-82) and pulmonary embolism (PE) (Inter-
national Classification of Diseases, 10th revision code: I26)
as primary diagnoses in the National Inpatient Register and
National Outpatient Register or Cause of Death Register.
All 3 registers were used to avoid underestimation of severe
cases of PE that may have only been captured as fatal in the
Cause of Death Register (2).
The following information on potential confounders was
also obtained. On the basis of information from the Na-
tional Patient Register, comorbidities were measured using
the Charlson comorbidity index (CCI), which assigns
weights to a number of medical conditions. Each condition
is assigned a score of 1, 2, 3, or 6, and the final CCI is given
as the sum of these scores (15). Individuals were grouped
into CCI categories for final scores of 0, 1, 2, or 3þ. In-
formation on age, serum prostate-specific antigen level,
treatment at time of diagnosis, tumor grade, and stage,
educational level, and history of TED was also used.
Prostate cancer risk category was defined according to a
modification of the National Comprehensive Cancer
Network guideline (16): low risk: T1-2, Gleason score 2 to
6, and PSA <10 ng/mL; intermediate risk: T1-2, Gleason
score 7, and/or PSA 10 to 20 ng/mL; high risk: T3 and/or
Gleason score 8 to 10 and/or PSA 20 to 50 ng/mL;
regionally metastatic/locally advanced: T4 and/or N1 and/
or PSA 50 to 100 ng/mL in the absence of distant metas-
tases (M0 or MX); and distant metastases: M1 and/or PSA
>100 ng/mL. Information on surgeries was taken from the
National Patient Register and included transurethral
resection of the prostate (TURP), open or laparoscopic
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radical prostatectomy, pelvic lymph node dissection, and
orchiectomy (3). Information on filled prescriptions of
anti-androgens and gonadotropin-releasing hormone ago-
nists was obtained from the National Prescribed Drug
Register, in which all filled prescriptions have been regis-
tered since July 1, 2005. This allowed us to create a time-
updated covariate for adjuvant and neoadjuvant ADT.
Disease progression was defined by using the following
proxy variables as time-dependent covariates: transurethral
resection of the prostate indicating infravesical obstruction;
palliative RT indicating a rise in serum PSA level or skel-
etal pain; and use of nephrostomy indicating overgrowth on
the ureter. This is consistent with previously published
work on the association between ADT and TED (13).
Statistical analysis
First we conducted univariate Cox proportional hazards
models to evaluate the association between known clinical
risk factors (ie, lymph node dissection, palliative RT, ADT
due to disease progression, hydronephrostomy, none
prostate cancer related surgeries) and TED. This then
confirmed the need to take these factors into account as
time-updated covariates in our multivariate models. To
further justify our choice for time-updated covariates
related to PCa only, we performed a sensitivity analysis in
which we censored for these events (eg, ADT for disease
progression) or used delayed entry (eg, 1 year after lymph
node dissection). The results were virtually the same as for
the adjusted models (results not shown). Univariate and
multivariate Cox proportional hazards models with age as a
time-scale were then conducted to determine the hazard
ratios (HRs) and 95% confidence intervals (CIs) for risk of
DVT and PE by types of RT (brachytherapy [BT] and
external beam RT [EBRT]). The assumption of propor-
tionality of the Cox model covariates was tested by plotting
Schoenfeld residuals (17). The multivariate analyses were
conducted stepwise, allowing us to identify the effect of
each confounder: CCI, education, PCa risk categories, PCa-
related surgeries, history of TED, disease progression
markers, other surgeries, adjuvant and neoadjuvant ADT.
Exposure to surgeries, neoadjuvant and adjuvant ADT, and
markers of disease progression were incorporated as time-
updated covariates. Because of the rather small sample
size for BT, we only performed an additional stratified
analysis by time since RT for EBRT: 0 to 6 months, 6 to
12 months, 1 to 2 years, and >2 years.
Data management was performed using SAS version 9.3
(SAS Institute, Cary, NC), and data analysis was conducted
with R version 2.13.2 (R Foundation for Statistical
Computing, Vienna, Austria).
Results
Between 1996 and 2013, 9410 men received curative RT as
registered in PCBaSe Sweden, out of which 6232 under-
went EBRT and 3178 BT. The latter group consisted of
patients receiving either high-dose-rate BT to the prostate
(nZ2452), combined with EBRT in the majority of the
patients, or low-dose-rate BT via implanted radioactive
seeds (nZ726). There were a total of 144 TED events in
the exposed groups (43 in the BT group and 101 in the
EBRT group) and 483 in the comparison cohort. Baseline
characteristics of the study cohort are presented in Table 1.
Univariate analyses for the association between known
TED risk factors and PE and DVT are presented in Table 2,
PCBaSe Sweden
PCa men who underwent RT as curative
treatment between
1996 and 2013 N=9,410
Exposed Unexposed
Matched cohort Pca-free men
N=46,826
EBRT N=6,232 BT N=3,178
Fig. 1. Selection of study population from Prostate Cancer Database Sweden.
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confirming the need for time-updated covariates in the
multivariate analyses.
There was a positive association between EBRT and BT
and the risk of PE, although after adjusting for CCI, PCa
risk category, PCa-related surgeries, previous TED, disease
progression markers, other surgeries, education, adjuvant
ADT, and neoadjuvant ADT it was no longer statistically
significant (HR 1.05, 95% CI 0.61-1.79; and HR 0.97, 95%
CI 0.29-1.44, respectively) (Table 3). In the stratified
analysis, the highest HR was observed for the first period
(0-6 months); however, after adjustment for the named
covariates it remained not statistically significant (data not
shown). No associations between EBRT or BT and the risk
of DVTwere found. Residual plots for all covariates versus
time at risk showed the residuals centered around zero,
indicating no violation of the hazards proportionality
assumption.
Discussion
The present study shows that in a cohort of Swedish men
with PCa, curative RT for prostate cancer was not associ-
ated with an increased risk of TED. Our analyses compare
men with PCa receiving RT with matched men from the
general population, so that our results cannot entirely
disentangle the effects of RT and the tumor itself on
development of TED. The observed lack of an association
Table 1 Baseline characteristics of PCBaSe
Characteristic
BT EBRT PCa-free men
n % n % n %
Total no. of men 3178 100 6232 100 46,826 100
Age (y)
<60 490 15.4 566 9.1 5299 11.3
60-64 772 24.3 1179 18.9 9678 20.7
65-74 1747 55.0 3827 61.4 27,706 59.2
75þ 169 5.3 660 10.6 4143 8.8
CCI
0 2574 81.0 4632 74.3 35,975 76.8
1 382 12.0 935 15.0 5751 12.3
2 158 5.0 436 7.0 2944 6.3
3þ 64 2.0 229 3.7 2156 4.6
Stage group
No PCa 0 0.0 0 0.0 46,826 100.0
Low risk 864 27.2 900 14.4 0
Intermediate risk 1059 33.3 2387 38.3 0
High risk 1106 34.8 2503 40.2 0
Regionally metastatic 126 4.0 391 6.3 0
Missing data 23 0.7 51 0.8 0
Prior DVT
0 3171 99.8 6190 99.3 46,529 99.4
1 7 0.2 38 0.6 140 0.3
2þ 0 0.0 4 0.1 157 0.3
Prior PE 0.0
0 3151 99.2 6157 98.8 46,497 99.3
1 26 0.8 65 1.0 146 0.3
2þ 1 0.0 10 0.2 183 0.4
Neoadjuvant ADT
No ADT 1029 32.4 2463 39.5 46,826 100.0
AA 200 6.3 309 5.0 0
GnRH 1949 61.3 3460 55.5 0
Educational level
Low 869 27.3 2279 36.6 16,861 36.0
Middle 1333 41.9 2525 40.5 18,684 39.9
High 959 30.2 1388 22.3 10,652 22.7
Missing 17 0.5 40 0.6 629 1.3
Follow-up time (y), mean (SD) 5.1 (2.1) 4.6 (2.1) 4.7 (2.2)
Abbreviations: AAZ anti-androgens; ADTZ androgen deprivation therapy; BTZ brachytherapy; CCIZ Charlson comorbidity index; DVTZ deep
venous thrombosis; GnRH Z gonadotropin-releasing hormone agonist; PCa Z prostate cancer; PCBaSe Z Prostate Cancer data Base Sweden;
PE Z pulmonary embolism.
Adjuvant ADT: BR group (AA Z 222, GnRH Z 134); EBRT group (AA Z 484, GnRH Z 678).
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between RT and TED when comparing with the general
population can be explained by one of the following rea-
sons: (1) RT is truly not associated with risk of TED; or (2)
men receiving RT are heavily selected according to their
TED risk factors so that a potential increased risk of TED
from RT is at most as big as the risk reduction due to the
selection. However, because cancer itself is a risk factor for
TED, this indicates that the second explanation is unlikely.
To the best of our knowledge, no large study to date has
investigated the association between RT for prostate cancer
and TED. Experimental data show that RT can induce
changes in artery walls, sinusoids, and capillaries (7). The
different layers of the wall vessels can suffer several al-
terations after radiation exposure, such as endothelial cell
damage, neointima lipid deposit, necrosis, fibrosis rupture,
and thrombosis (7, 18). Moreover, EBRT to the pelvis has
been found to increase the risk of bleeding in men who
were on an anticoagulant scheme before receiving RT (19).
Less evidence has been found for large veins (20), except
for hepatic and large intestine veins, which RT frequently
affects. Little is known regarding the biological mecha-
nisms for this lesser impact of RT in large veins, although it
has been suggested that large veins that do get affected by
RTwere probably invaded by the neoplasm before RT (20).
Our results suggest that large veins from the pelvic area of
patients who received RT for PCa do not seem to suffer
enough alterations that can lead to a short-term thrombo-
embolic event. However most of the reported RT changes in
the arteries and heart seem to happen several years after
receiving RT, and our mean follow-up time was 5 years, so
that the present study may not be sensitive for long-term
events.
Men who undergo radical prostatectomy are at a slightly
increased risk of TEDs (2). Moreover, results from a recent
observational showed that ADT also increases the risk of
TED (13). In our analysis we included adjuvant and neo-
adjuvant ADT as potential confounders; however, this
adjustment did not alter the final point estimates for the
association.
A major strength of our study is the use of compre-
hensive data in PCBaSe Sweden, a large nationwide
population-based register from which information on
complete follow-up, PCa treatment, PCa stage, surgeries,
disease progression, ADT, comorbidities, and socioeco-
nomic status can be retrieved, which allowed us to adjust
for known TED risk factors. Additionally, the use of a PCa-
free, age- and residence-matched comparison cohort
allowed for accurate risk estimation. The availability of
data regarding delivered RT doses for this large cohort is
another strength of this study. It allowed us to confirm that
the selected patients had received radiation doses with
curative potential to the prostate.
Detailed information on irradiated volumes was lacking,
which excluded the possibility of examining doseevolume
effects on TED. Even though we had data on type and
dosage of EBRT, it was not possible to divide this further
into subtypes owing to the low number of TED events.
However, it is unlikely that we have missed strong
Table 2 Univariate hazard ratios (HRs) and 95% confidence intervals (CIs) for risk of DVT and PE according to known clinical risk
factors for TED




BT EBRT HR 95% CI HR 95% CI
PCa men
Lymph node dissection (LND within last 12 mo
vs no LND within last 12 mo)
759 1166 2.03 0.82-4.99 3.44 0.80-14.76
Palliative RT 25 90 1.68 0.23-12.06 17.72 4.16-75.47
AA due to disease progression vs no AA 181 665 1.09 0.50-2.58 2.64 0.92-7.56
GnRH due to disease progression 183 537 2.46 1.30-4.65 9.41 3.83-23.06
Hydronephrostomy 4 24 7.56 1.03-55.44 NA* NA
Non-PCa related surgeriesy 427 863 7.83y 4.88-12.56 5.04y 1.86-13.62
Abbreviations: EBRT Z external beam radiation therapy; LND Z lymph node dissection; NA Z nonapplicable; TED Z thromboembolic disease.
Other abbreviations as in Table 1.
* No events.
y PCa-free men included for this variable (no. of events Z 5106).




HR 95% CI HR 95% CI
No RT 1.00 Reference 1.00 Reference
Unadjusted
BT 0.60 0.26-1.36 1.47 1.05-2.07
EBRT 1.09 0.68-1.74 1.73 1.35-2.2
Adjusted*
BT 0.34 0.08-1.11 0.97 0.29-1.44
EBRT 0.44 0.14-1.4 1.05 0.61-1.79
Abbreviations as in Tables 1 and 2.
* Charlson comorbidity index, PCa risk category, PCa-related sur-
geries, previous thromboembolic events, TED known risk factors as
determined in Table 2, education, adjuvant ADT, and neoadjuvant
ADT.
Bosco et al. International Journal of Radiation Oncology  Biology  Physics1030
associations because none of our findings suggested any
indication of a positive trend. Additional limitations include
lack of information on lifestyle factors and residual con-
founding, which could not be accounted for (21, 22).
However, adjustment for CCI and history of TED served as
proxies for lifestyle and health status at initiation of RT.
Conclusion
Our data indicate that curative RT for PCa is not associated
with the risk of developing PE or DVT.
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